Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - InterMune, Inc. (NasdaqNM:ITMN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Location
1710 Gilbreth Road, Suite 301
Burlingame, CA 94010
Phone: (650) 409-2020
Fax: (650) 259-0774
Email: info@intermune.com
Employees (last reported count): 91
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 46%
·Over the last 6 months:
 · 3 insider buys; 7,000  shares
 · 2 insider sells; 101.0K shares
  (0.8% of insider shares)
·Institutional: 52% (96% of float)
(196 institutions)
·Net Inst. Buying: 6.32M shares (+30.00%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
InterMune, Inc., formerly known as InterMune Pharmaceuticals, Inc., develops and commercializes products for the treatment of serious pulmonary and infectious diseases and congenital disorders. The Company has the exclusive license rights in the United States to ActImmune for a range of diseases, including chronic granulomatous disease, a life-threatening congenital disorder of the immune system; osteopetrosis, a life-threatening congenital disorder causing an overgrowth of bony structures; idiopathic pulmonary fibrosis, a life-threatening lung condition; infections caused by a type of bacteria known as mycobacteria (mycobacterial infections), such as tuberculosis; infections caused by various fungi that attack patients with weakened immune systems (systemic fungal infections), such as cryptococcal meningitis and pneumonia; and cystic fibrosis, a congenital disorder that leads to chronic pulmonary infections in children.
More from Market Guide: Expanded Business Description

Financial Summary
InterMune develops and commercializes innovative products for the treatment of serious pulmonary and infectious diseases and congenital disorders. The Co. has the exclusive sublicense rights in the United States to ACTIMMUNE. For the six months ended 6/01, revenues totalled $13.6 million, up from $3.1 million. Net loss applicable to Common fell 29% to $28.8 million. Results reflect increased sales of ACTIMMUNE, and the absence of preferred dividend obligations.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

W. Scott Harkonen, M.D., 49
Chairman, Pres, CEO
$306K
Timothy Lynch, 31
CFO, VP-Bus. Devel.
165K
James Pennington, M.D., 58
Exec. VP of Medical and Scientific Affairs
--  
Stephen Rosenfield, 51
Sr. VP- Legal Affairs, Gen. Counsel
221K
Peter Van Vlasselaer, Ph.D., 42
Sr. VP of Technical Operations
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ITMNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$12.50 
Recent Price$39.49 
52-Week High
on 26-Sep-2000
$55.875
Daily Volume (3-month avg)511.3K
Daily Volume (10-day avg)292.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-0.0%
52-Week Change
relative to S&P500
+34.1%
Share-Related Items
Market Capitalization$1.12B
Shares Outstanding28.3M
Float15.3M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$7.09 
Earnings (ttm)-$1.76 
Earnings (mrq)-$0.79 
Sales (ttm)$0.95 
Cash (mrq)$6.03 
Valuation Ratios
Price/Book (mrq)5.57 
Price/EarningsN/A 
Price/Sales (ttm)41.65 
Income Statements
Sales (ttm)$21.6M
EBITDA (ttm)-$47.3M
Income available to common (ttm)-$40.5M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-21.93%
Return on Equity (ttm)-22.89%
Financial Strength
Current Ratio (mrq)7.59 
Debt/Equity (mrq)0 
Total Cash (mrq)$144.5M
Short Interest
As of 8-Aug-2001
Shares Short2.18M
Percent of Float14.3%
Shares Short
(Prior Month)
1.79M
Short Ratio5.34 
Daily Volume409.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.